Literature DB >> 22213820

Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma.

Kai-Ping Chang1, Ngan-Ming Tsang, Chun-Ta Liao, Cheng-Lung Hsu, Ming-Jui Chung, Chuan-Wei Lo, Sheng-Chieh Chan, Shu-Hang Ng, Hung-Ming Wang, Tzu-Chen Yen.   

Abstract

UNLABELLED: The plasma concentration of Epstein-Barr virus (EBV) DNA is associated with tumor burden and prognosis in patients with nasopharyngeal carcinoma (NPC), but data on the relationship between viral load and (18)F-FDG PET functional parameters are lacking. We examined the association of (18)F-FDG PET functional parameters and EBV DNA load with the clinicopathologic characteristics and clinical outcomes of patients with NPC.
METHODS: One hundred eight patients with NPC who underwent (18)F-FDG PET before treatment were included in this study. We determined total lesion glycolysis (TLG) of the primary tumor, the cervical nodes, and their combination and the maximal standardized uptake value of the primary tumor and cervical lymph nodes. EBV DNA was measured by real-time polymerase chain reaction.
RESULTS: EBV DNA was significantly associated with total TLG (R(2) = 0.589). Total TLG values had the highest correlation with EBV DNA load and were significantly associated with tumor, nodal, and overall stages. However, tumor TLG greater than the median (>65 g) was the only parameter significantly associated with overall, local recurrence-free, disease-free, and distant metastasis-free survivals (P = 0.033, 0.014, <0.001, and 0.023, respectively). After allowance for potential confounders, tumor TLG retained its independent significance for overall and disease-free survival rates (P = 0.045 and 0.006, respectively).
CONCLUSION: Total TLG values are primarily associated with tumor burden and clinical stage, whereas tumor TLG is the best predictor of patient survival after treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22213820     DOI: 10.2967/jnumed.111.090696

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  47 in total

Review 1.  Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2015-10-27       Impact factor: 2.374

2.  [18F]-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Value as a Predictor of Adjuvant Chemotherapy Benefits in Patients With Nasopharyngeal Carcinoma.

Authors:  Te-Chun Hsieh; Ching Yun Hsieh; Tse Yen Yang; Tzu Ting Chen; Chen Yuan Lin; Ching-Chan Lin; Chung Hung Hua; Chang-Fang Chiu; Su-Peng Yeh; Yuh Pyng Sher
Journal:  Oncologist       Date:  2015-04-15

3.  Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma.

Authors:  Esther Mena; Mehdi Taghipour; Sara Sheikhbahaei; Abhinav K Jha; Arman Rahmim; Lilja Solnes; Rathan M Subramaniam
Journal:  Clin Nucl Med       Date:  2017-05       Impact factor: 7.794

4.  Human cytomegalovirus and Epstein-Barr virus infection impact on (18)F-FDG PET/CT SUVmax, CT volumetric and KRAS-based parameters of patients with locally advanced rectal cancer treated with neoadjuvant therapy.

Authors:  Claudio V Sole; Felipe A Calvo; Carlos Ferrer; Emilio Alvarez; Jose L Carreras; Enrique Ochoa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-01       Impact factor: 9.236

5.  Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer.

Authors:  Nai-Ming Cheng; Yu-Hua Dean Fang; Li-yu Lee; Joseph Tung-Chieh Chang; Din-Li Tsan; Shu-Hang Ng; Hung-Ming Wang; Chun-Ta Liao; Lan-Yan Yang; Ching-Han Hsu; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-23       Impact factor: 9.236

6.  Radiomics Analysis of PET and CT Components of PET/CT Imaging Integrated with Clinical Parameters: Application to Prognosis for Nasopharyngeal Carcinoma.

Authors:  Wenbing Lv; Qingyu Yuan; Quanshi Wang; Jianhua Ma; Qianjin Feng; Wufan Chen; Arman Rahmim; Lijun Lu
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

7.  Value of early evaluation of treatment response using 18F-FDG PET/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma.

Authors:  Yu-Hung Chen; Kai-Ping Chang; Sung-Chao Chu; Tzu-Chen Yen; Ling-Yi Wang; Joseph Tung-Chieh Chang; Cheng-Lung Hsu; Shu-Hang Ng; Shu-Hsin Liu; Sheng-Chieh Chan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-27       Impact factor: 9.236

8.  Adaptive Boost Target Definition in High-Risk Head and Neck Cancer Based on Multi-imaging Risk Biomarkers.

Authors:  Feifei Teng; Madhava Aryal; Jae Lee; Choonik Lee; Xioajin Shen; Peter G Hawkins; Michelle Mierzwa; Avraham Eisbruch; Yue Cao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-12-21       Impact factor: 7.038

9.  FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma.

Authors:  Vasavi Paidpally; Alin Chirindel; Stella Lam; Nishant Agrawal; Harry Quon; Rathan M Subramaniam
Journal:  Imaging Med       Date:  2012-12

10.  PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis.

Authors:  Bang-Bin Chen; Yu-Wen Tien; Ming-Chu Chang; Mei-Fang Cheng; Yu-Ting Chang; Chih-Horng Wu; Xin-Jia Chen; Ting-Chun Kuo; Shih-Hung Yang; I-Lun Shih; Hong-Shiee Lai; Tiffany Ting-Fang Shih
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-19       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.